Spero Therapeutics News

Express News | Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters16:07 ET

Express News | Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics

Moomoo 24/7Apr 4 09:45 ET

Express News | HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target

Moomoo 24/7Mar 18 07:02 ET

Spero Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/18/2024 300% HC Wainwright & Co. → $7 Reiterates Buy → Buy 11/14/2023 300% HC Wainwright & Co. → $7 Rei

BenzingaMar 18 07:01 ET

Spero Therapeutics' Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating

TipRanksMar 18 06:26 ET

Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Yahoo FinanceMar 17 09:01 ET

Spero Therapeutics Files $300M Mixed Securities Shelf

Seeking AlphaMar 15 16:45 ET

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 15 12:51 ET

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Yahoo FinanceMar 15 06:49 ET

Spero Therapeutics, Inc. (SPRO) Sees Surge in Pre-Market Trading

Spero Therapeutics, Inc. (NASDAQ: SPRO), a pioneering biopharmaceutical company specializing in treatments for bacterial infections and rare diseases, experienced a remarkable pre-market surge on Thursday, following a static day on Wednesday. The stock exhibited a sudden climb of 15%, indicating significant investor interest. This surge appears to be directly linked to the recent earnings release. ...

Stocks TelegraphMar 14 08:37 ET

Express News | Spero Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results

Moomoo 24/7Mar 14 08:04 ET

TD Cowen Sticks to Its Hold Rating for Spero Therapeutics (SPRO)

TipRanksMar 13 23:25 ET

Earnings Call Summary | Spero Therapeutics(SPRO.US) Q4 2023 Earnings Conference

The following is a summary of the Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript:Financial Performance:Spero Therapeutics reported having cash and cash equivalents worth $76.3 millio

moomoo AIMar 13 17:55 ET · Conference Call

Recap: Spero Therapeutics Q4 Earnings

Spero Therapeutics (NASDAQ:SPRO) reported its Q4 earnings results on Wednesday, March 13, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsSpero Therapeutics beat est

BenzingaMar 13 16:15 ET

Spero Therapeutics Q4 2023 GAAP EPS $0.96 Beats $(0.10) Estimate, Sales $73.524M Beat $18.633M Estimate

Spero Therapeutics (NASDAQ:SPRO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $(0.10) by 1060 percent. This is a 74.55 percent increase over earnings of

BenzingaMar 13 16:12 ET

Spero Therapeutics Reiterates Expected Cash Runway Into Late 2025 >SPRO

Spero Therapeutics Reiterates Expected Cash Runway Into Late 2025 >SPRO

Dow JonesMar 13 16:03 ET

Spero Therapeutics 4Q Rev $73.5M >SPRO

Spero Therapeutics 4Q Rev $73.5M >SPRO

Dow JonesMar 13 16:01 ET

Press Release: Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update -- On track for topline data from SPR720 Phase 2a proof-of-concept trial in tr

Dow JonesMar 13 16:01 ET

Earnings Scheduled For March 13, 2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. • Silence Therapeutics (NASDAQ:SLN) is expec

BenzingaMar 13 06:15 ET

Spero Therapeutics Q4 2023 Earnings Preview

Seeking AlphaMar 12 17:35 ET